Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 4/20 | 0.47 |
| ▸ | AXL | P30530 | 4/20 | 0.47 |
| ▸ | PRKCI | P41743 | 4/20 | 0.47 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2318359 | 0.79 | CCNK (0.46) | NUDT1AXLPRKCICDK8MAPK1 | |
| SCHEMBL14697441 | 0.76 | CCR8 (0.52) | NUDT1AXLPRKCIJAK2JAK3 | |
| SCHEMBL14697443 | 0.76 | PRKCI (0.41) | NUDT1AXLPRKCIMAPK1JAK2 | |
| SCHEMBL30381637 | 0.73 | KDM4E (0.50) | NUDT1AXLPRKCICDK8MAPK1 | |
| SCHEMBL12612679 | 0.73 | PRKCI (0.46) | NUDT1AXLPRKCICDK8MAPK1 | |
| SCHEMBL2223296 | 0.72 | PRKCI (0.44) | NUDT1AXLPRKCICDK8MAPK1 | |
| SCHEMBL455351 | 0.72 | KDM4E (0.53) | AHR | |
| SCHEMBL12424590 | 0.71 | PRKCI (0.47) | NUDT1AXLPRKCIMAPK1JAK2 | |
| SCHEMBL29588119 | 0.71 | PRKCI (0.47) | NUDT1AXLPRKCIMAPK1JAK2 | |
| SCHEMBL28735162 | 0.71 | PRKCI (0.40) | NUDT1AXLPRKCIMAPK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | disclosed |
| CN-115385911-A | Compound with dipyrrolopyridine structure, preparation method and medical application | 南京康屹生物医药中心(有限合伙) | 2022-11-25 | — | — | CN | disclosed |
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2018-10-11 | — | — | US | disclosed |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| EP-3031324-A2 | TRICYCLIC KINASE INHIBITORS | AbbVie Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9365579-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2299821-B1 | TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150210708-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-8962629-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20090312338-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | US | disclosed |
| US-20070191420-A1 | Kinase inhibitors | DEVGEN NV | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | NUDT1 1598/4885AXL 3812/4885PRKCI 3201/4885 |
| US-20090312338-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | NUDT1 1598/4885AXL 3812/4885PRKCI 3201/4885 |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | NUDT1 1598/4885AXL 3812/4885PRKCI 3201/4885 |
| US-20150210708-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | NUDT1 1598/4885AXL 3812/4885PRKCI 3201/4885 |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | NUDT1 1598/4885AXL 3812/4885PRKCI 3201/4885 |
| US-20070191420-A1 | Kinase inhibitors | ROCK1, ROCK2, MAP3K20 | NUDT1 3875/4885AXL 673/4885PRKCI 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.